Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00054795 · ClinicalTrials.gov registry record · Phase 3

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

A Phase 3 study of Carcinoma, Non-Small Cell Lung and Brain Neoplasms, sponsored by Pharmacyclics.

Completed
Registry status
Phase 3
Development phase
550
Enrollment target
20
Study locations

NCT00054795 is a Phase 3 study of Carcinoma, Non-Small Cell Lung and Brain Neoplasms that has completed, run by Pharmacyclics. The registered enrollment target is 550 participants, above the 320-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (72% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00054795, a Phase 3 study of Carcinoma, Non-Small Cell Lung and Brain Neoplasms, has completed, sponsored by Pharmacyclics.

COMPLETED
Registry status
Phase 3
Development phase
550 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of the study is to determine if patients with brain metastases from non-small cell lung cancer treated with Motexafin Gadolinium and whole brain radiation therapy retain their neurologic function and ability to think for a longer time compared to patients treated with whole brain radiation therapy alone.

Conditions Studied

Carcinoma, Non-Small Cell Lung Brain Neoplasms Metastases, Neoplasm

Interventions

  • DRUG Motexafin Gadolinium

Study Locations (20)

California

  • - Berkeley
  • - Concord
  • - Greenbrae
  • - Los Angeles
  • - Montebello
  • - Sacramento
  • - Stanford

Arkansas

  • - Fort Smith
  • - Little Rock

Connecticut

  • - Hartford
  • - New Haven

Indiana

  • - Fort Wayne
  • - Indianapolis

Maryland

  • - Baltimore
  • - Washington D.C

Arizona

  • - Phoenix

Colorado

  • - Aurora

Illinois

  • - Chicago

Trial Details

FieldValue
Enrollment Target 550 participants
Phase Phase 3

Sponsor

Pharmacyclics

54 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00054795

The ClinicalTrials.gov registry entry for NCT00054795 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 320-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (72% higher). The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 1 intervention - of which Motexafin Gadolinium is the first listed.

NCT00054795 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Arkansas, Connecticut.

Frequently Asked Questions

What is clinical trial NCT00054795 about?

NCT00054795 is a clinical study titled "Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)". The primary purpose of the study is to determine if patients with brain metastases from non-small cell lung cancer treated with Motexafin Gadolinium and whole brain radiation therapy retain their neurologic function and ability to think for a longer time compared to patients treated with whole brain...

What is the current status of trial NCT00054795?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 550 participants.

What conditions does trial NCT00054795 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Brain Neoplasms, Metastases, Neoplasm.

What interventions are being tested in trial NCT00054795?

The interventions under investigation include: Motexafin Gadolinium (DRUG).

Who is sponsoring clinical trial NCT00054795?

This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00054795 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Brain Neoplasms

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.